【藥品性質提示】 根據 2019 AGS Beers Criteria，本藥品為【潛在不適當用藥 (PIM)】，不建議用於有骨折風險之老年人(除非用於急性止痛)。 #高警訊藥品

類鴉片止痛 Relief of moderate to severe pain, supplement to balanced anesthesia, pre-op and post- op analgesia; obstetrical analgesia during labor and delivery

Analgesic, Opioid Partial Agonist
Agonist of kappa opiate receptors and partial antagonist of mu opiate receptors in the CNS, causing inhibition of ascending pain pathways, altering the perception of and response to pain; produces generalized CNS depression

1. Onset of action, Peak effect: (SubQ, IM) <15 minutes; (IV) 2 to 3 minutes
2. Duration of action: 3 to 6 hours
3. Protein binding: ~50%
4. Metabolism: Hepatic; extensive first-pass metabolism
5. Half-life elimination: (Children) 0.9 to 3.5 hours; (Adults) 5 hours
6. Excretion: Feces; urine (~7% eliminated as unchanged drug and metabolites)

Hypersensitivity to Nalbuphine Hydrochloride or any ingredients.

B

Enters breast milk (less 1%); use caution

Sedation, sweaty, nausea, vomiting, dizziness, vertigo, dry mouth, headache

Pain management: IM, IV, SubQ
1. Usual 10 mg every 3 to 6 hours as needed (based on a 70 kg patient); may titrate dose to appropriate effect
2. Maximum: 20 mg/dose; 160 mg/day
Surgical anesthesia supplement: IV
1. Induction: 0.3 to 3 mg/kg over 10 to 15 minutes
2. Maintenance: 0.25 to 0.5 mg/kg as required

0.1-0.2 mg/kg every 3-4 hours as needed; MAX 20 mg/dose and/or 160 mg/day

There are no specific dosage adjustments provided in the manufacturer's labeling; however, a reduced dose is recommended.

There are no specific dosage adjustments provided in the manufacturer's labeling; however, a reduced dose is recommended.